Factor VIII Antikörper

Produktnummer ABIN7101888

Der Maus Monoklonal anti-Factor VIII Antikörper (Klon 101) (ABIN7101888) detektiert spezifisch Factor VIII in WB und EIA. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Factor VIII Antikörper (ABIN7101888)

Target: Factor VIII (F8) (Coagulation Factor VIII (F8))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Factor VIII Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Klon: 101

Produktdetails anti-Factor VIII Antikörper

Spezifität: This antibody recognizes full-length Factor VIII. Does not cross-react with von Willebrand factor.

Produktmerkmale: Synonyms: Procoagulant component, Antihemophilic factor, F8C, AHF

Aufreinigung: Protein G chromatography

Immunogen: Purified human Factor VIII

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA. Western Blot.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1,0 mg/mL (OD280nm)

Buffer: PBS, pH 7.4

Lagerung: -20 °C

Informationen zur Lagerung: Store the antibody at -20 °C. Avoid repeated freezing and thawing.
Shelf life: one year from despatch.

Haltbarkeit: 12 months

Details zu Factor VIII

Target: Factor VIII (F8) (Coagulation Factor VIII (F8))

Hintergrund: Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50 % of patients have severe hemophilia A with F8C activity less than 1 % of normal, they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10 % of patients, F8C activity is 2-5 % of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40 % of patients, is associated with F8C activity of 5-30 % and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5 %) that have considerable amount of F8C in their plasma (at least 30 % of normal), but the protein is nonfunctional, i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.Synonyms: AHF, Antihemophilic factor, F8C, Procoagulant component

Gen-ID: 2157

UniProt: P00451